3 ms·
Improving how much? Feom what I've seen its still mostly a death sentence
by DoesntMatter22 3y ago
Improving how much? Feom what I've seen its still mostly a death sentence
- Spooky23 3y agoWith one of the checkmate trials, the median 5 year survival rate for patients taking nivolumab and ipilimumab is 5 years. The patients in this study trended older and had inoperable brain mets. The survival rate previously was something like 9-12 months. https://www.nejm.org/doi/full/10.1056/nejmoa1910836 https://www.nejm.org/doi/full/10.1056/nejmoa1910836
- starkparker 3y agoMore recent 3- and 4-year Phase 3 CheckMate metastatic non-small cell lung cancer trial results were also good, if less dramatic. ESMO summary: https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/long-term-event-free-survival-benefits-of-neoadjuvant-nivolumab-plus-chemotherapy-for-resectable-nsclc https://dailyreporter.esmo.org/european-lung-cancer-congress... 4-year trial PR: https://news.bms.com/news/details/2023/Four-Year-Outcomes-from-Phase-3-CheckMate--9LA-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-with-Two-Cycles-of-Chemotherapy-for-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx https://news.bms.com/news/details/2023/Four-Year-Outcomes-fr... 3-year trial abstract: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8521 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8521
- DoesntMatter22 3y agoWell it still sounds like a death sentence. Just a few your years